Answer
Erdafitinib may reduce hormonal contraceptive efficacy, so patients should use an alternative contraceptive unaffected by enzyme inducers or additional nonhormonal contraception during treatment and until one month after the last dose.
Sources for this answer
- Balversa 3mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked